5,8-Dimethyl-s-triazolo<1,5-c>pyrimidin | 69141-86-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: 5,8-Dimethyl-s-triazolo<1,5-c>pyrimidin
• 英文别名: 5,8-dimethyl-[1,2,4]triazolo[1,5-c]pyrimidine；5,8-Dimethyl[1,2,4]triazolo[1,5-c]pyrimidine；5,8-dimethyl-[1,2,4]triazolo[1,5-c]pyrimidine
• CAS: 69141-86-2
• 化学式: C₇H₈N₄
• 分子量: 148.167
• InChiKey: UZDAJFBGOBDVHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5,8-Dimethyl-s-triazolo<1,5-c>pyrimidin 生成 N-[(E)-2-(1H-1,2,4-triazol-5-yl)prop-1-enyl]acetamide
  参考文献：
  名称：

  BROWN D. J.; NAGAMATSU T., AUSTRAL. J. CHEM., 1978, 31, NO 11, 2505-2515

  摘要：

  DOI：
• 作为产物：
  描述：

  2,5-二甲基-1,3,7,8-四氮杂双环[4.3.0]壬-2,4,6,8-四烯 以83%的产率得到
  参考文献：
  名称：

  BROWN D. J.; NAGAMATSU T., AUSTRAL. J. CHEM., 1978, 31, NO 11, 2505-2515

  摘要：

  DOI：

文献信息

• LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：INTERMUNE, INC.

  公开号：US20140200215A1

  公开（公告）日：2014-07-17

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

  提供的是化合物、制造这些化合物的方法、包含这些化合物的药物组合物和药品，以及使用这些化合物来治疗、预防或诊断与一个或多个溶血磷脂酸受体相关的疾病、失调或状况的方法。
• [EN] IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOLE UTILISÉS COMME INHIBITEURS D'ENZYMES PDE10A
  申请人：LUNDBECK & CO AS H

  公开号：WO2013107856A1

  公开（公告）日：2013-07-25

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  这项发明涉及一种PDE10A酶抑制剂化合物。该发明提供了包括该发明化合物的治疗有效量和药用载体的药物组合物。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者投予式I化合物的治疗有效量。本发明还提供了一种治疗患有药物成瘾的受试者的方法，包括向受试者投予式I化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者投予式I化合物的治疗有效量。
• [EN] IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOLE COMME INHIBITEURS DE L'ENZYME PDE10A
  申请人：LUNDBECK & CO AS H

  公开号：WO2013127817A1

  公开（公告）日：2013-09-06

  This invention is directed to compounds (I), which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula. The present invention further provides a compound of formula (I) for use in treating a subject suffering from a neurodegenerative disorder, a drug addiction or a psychiatric disorder (formula I), wherein HET is a heteroaromatic group of formula II containing from 2 to 4 nitrogen atoms: (formula II).

  该发明涉及化合物（I），这些化合物是PDE10A酶抑制剂。该发明提供了一种包括该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备上述化合物的方法。本发明还提供了一种用于治疗患有神经退行性疾病、药物成瘾或精神障碍的患者的化合物（式I），其中HET是一个含有2至4个氮原子的式II杂环芳烃基团：（式II）。
• [EN] HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 杂环化合物及其制备方法和用途
  申请人：SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD

  公开号：WO2022042331A1

  公开（公告）日：2022-03-03

  本发明涉及杂环化合物及其制备方法和用途。具体地，本发明涉及式(I)的化合物或其药学上可接受的盐、酯、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药、其制备方法、包含其的药物组合物及其在预防和治疗相关疾病中的用途。
• AZAHETEROARYL COMPOUND AND APPLICATION THEREOF
  申请人：Blueray Therapeutics (Shanghai) Co., Ltd

  公开号：EP4019521A1

  公开（公告）日：2022-06-29

  Disclosed in the present disclosure are an azaheteroaryl compound, a pharmaceutically acceptable salt thereof, and a solvate thereof. The present disclosure also provides a method for preparing said compound, a composition containing said compound, and a use of said compound in the preparation of a drug for treating a disease or disorder related to the mechanism of action of an EED protein and/or a PRC2 protein complex. (Formula 1)

  本公开揭示了一种氮杂杂环化合物及其药学上可接受的盐和溶剂化物。本公开还提供了一种制备该化合物的方法、含有该化合物的组合物以及将该化合物用于制备用于治疗与EED蛋白和/或PRC2蛋白复合物作用机制相关的疾病或障碍的药物的用途。(式1)